The choice of induction chemotherapy was based on its high ORR of 97% after 2 treatment cycles in limited-disease SCLC.23 This suggests that for most patients, this approach could promote tumor shrinkage and separation from surrounding vasculature, thereby reducing the bleeding risk associated with anti-VEGFR agents. The gene discussed is KDR; the disease is neoplasm.